Acdemic Qualification:
Ph.D in Science: Chemistry. Awarded in 1999, University of Delhi, India.
M.Sc.: Chemistry, Awarded in 1994, University of Delhi, India.
Academic positions:
Scientist F, Institute of Life Sciences, Bhubaneswar – 2021 – Cont.
Scientist E, Institute of Life Sciences, Bhubaneswar – 2016 – 2020
Scientist D, Institute of Life Sciences, Bhubaneswar – 2010 – 2015
Scientist C, Institute of Life Sciences, Bhubaneswar – 2007- 2010
Scientist B, Institute of Life Sciences, Bhubaneswar – 2005 – 2007
Research Associate, University of Nebraska Medical Center, Omaha, NE, USA- July 2004 to June 2005
Postdoctoral Research Associate, University of Nebraska Medical Center. Omaha, NE, USA.- September 2001 to June 2004
Postdoctoral Research Fellow, JSPS Postdoctoral fellow, Kumamoto University School of Medicine, Kumamoto, Japan- August 1999 to August 2001
Scientist, Dabur Research Foundation. Dabur India Ltd., India- March 1999 to August 1999
Research Fellow, University of Nottingham, Nottingham, U. K.- January 1998 to March 1998
Awards and Recognition:
• Listed amongst World’s top 2% highly cited Scientists by Stanford University in 2020.
• Highly Cited Researcher in 2018 in the field of pharmacology and toxicology from Clarivate Analytics, USA.(Recognised as one of the top 10 Scientists from India in the list of top 4000 Scientists across the globe.
• Awarded Samanta Chandrasekhar Award from Odisha Bigyan Academy Govt. of Odisha in 2011.
• Awarded International Fellowship for Young Biomedical Scientists in 2008 from ICMR to work at Creighton University, Omaha, Nebraska, USA.
• Awarded Postdoctoral fellowship from the American Heart Association (AHA), United States of America (2002-2004).
• Awarded Japanese Society for Promotion of Science (JSPS) postdoctoral fellowship from the Government of Japan (1999-2001).
• Awarded Senior Research Fellowship (SRF, 1998-1999), University Grant Commission, Government of India.
• Awarded travel grants from University of London to attend the 3rd International symposium on Polymer Therapeutics from Laboratory to Clinical Practice, School of Pharmacy, University of London, UK, 1998.
• Awarded Junior Research Fellowship (JRF, 1996-98) University Grant Commission, Government of India.
• Secured (84.07 percentile) All India Graduate Aptitude Test in Engineering (GATE) in 1996.

Membership of Professional Associations / Societies:
• Section Editor (Cancer), Current Pharmaceutical Biotechnology
• Member, Editorial Board, Current Nanomedicine
• Member, Editorial Board, Clinical & Experimental Pharmacology
• Member, Editorial Board, Future Nanomedicine

Reviewer of Scientific Journals:
Journal of Colloid and Interface Science, Biomacromolecules, Journal of Biomedical Nanotechnology, Drug Discovery Today, Export Opinion in Drug Delivery, Asain Journal of Pharmaceutics, Biomedical Materials, Future Nanomedicine, International Journal of Nanomedicine, Journal of Physics Condensed Matter, Nanotechnology, Expert Review of Molecular Diagnostics, Biomaterials, Nanomedicine: Nanotechnology, Biology and Medicine, Current Nanosciences, Pharmaceutical Research, Journal of Controlled Release, Biomacromolecules, Journal of Ameican Chemical Scociety, Small, Europian Journal of Pharmaceutics and Biopharmaceutics, Therapeutic Delivery, Tumor Biology, Chinise Medicine, future Oncology, Nanotechnology, Journal of Biomaterials Application, Cancer research, Macromolecular Biosciences, ACS Nano, Advanced Healthcare Biomaterials, Oncotarget.

Nanomedicine mediated targeting of Cancer Stem-Like Cells

Chemoresistance and cancer relapse marks the significant challenges in cancer management and are attributable in part to the presence of cancer cells subpopulations termed as cancer stem cells or tumor initiating cells. Although their mode of generation and biological properties has been explored in diverse array of cancer types, our understanding of the biology of the CSCs remains superficial. Due to their extraordinary characteristics, CSCs are thought to be the basis for tumor initiation, development, metastasis and recurrence. Researchers have identified multiple potential therapeutic targets to CSCs, including the ABC superfamily, anti-apoptotic factors, detoxifying enzymes, DNA repair enzymes and distinct oncogenic cascades (such as the Wnt/β-catenin, hedgehog, EGFR and Notch pathways) which are used preferentially or uniquely by these cells. Evidences exists indicating that non-CSCs in the tumor can spontaneously and stochastically turn into CSCs de novo, undermining the efficacy of therapeutic strategy that only targets CSCs. Hence, it becomes crucial to eliminate both CSCs and non-CSCs simultaneously for effective cancer therapy. Our group is thus working on combinational approach for effective cancer treatment. We have focused our studies based on dual drug delivery systems targeting CSCs specific signaling pathway and simultaneously targeting non-CSCs to get rid of cancer relapse and metastasis in both in-vitro and in-vivo models.

Magnetic nanoparticles as a theranostic tool in cancer therapy

Development of magnetic nanoparticles (MNPs) as a theranostic agent in cancer therapy has growing importance due to their application both as a drug delivery agent for therapeutic purpose and imaging agent for diagnostic purpose. The role of MNPs as a contrast agent for the magnetic resonance imaging (MRI) has gained significant attention in cancer therapy as early diagnosis of cancer has always remained a challenge. Further, the therapeutic applications of magnetic nanoparticles account for targeted delivery of therapeutic agents and also another upcoming therapeutic mode of treatment for cancer i.e, hyperthermia. MNPs in presence of alternating magnetic field can induce heat that can kill the cancer cells and may enhance the therapeutic index of the chemotherapeutic drugs and also may help in eliminating the cancer stem cells that are the major cause of relapse of cancer. However, the majority of research in this area is still at the bench side and clinical translation is restricted by instability of the MNPs. Thus, development of aqueous dispersible magnetic nanoparticles having sufficient magnetization is necessary that can be used for different biomedical applications like drug delivery, contrast agent for MRI, hyperthermia, cell separation etc. In this regard, we have synthesized an aqueous dispersible highly stable polymer coated magnetic nanoparticle formulation (Indian Patent Application No 779/KOL/2009 of 21/5/2009 and International PCT Application No.PCT/IN09/000639 of 12/11/2009). Our lab is extensively using the above MNPs formulation for different biomedical applications for cancer management.

Publication
Total no of publications = 101
Below the publications in last ten years (2010-2020)

1. Mohapatra P, Singh P, Sahoo SK.(2020) Phytonanomedicine: a novel avenue to treat recurrent cancer by targeting cancer stem cells. Drug Discov Today, 25(8),1307-1321.

2. Kundu P, Singh D, Singh A, Sahoo SK.(2020) Cancer Nanotheranostics: A Nanomedicinal Approach for Cancer Therapy and Diagnosis. Anticancer Agents Med Chem. 20(11),1288-1299.

3. Singh A, Jain S, Sahoo SK.(2020) Magnetic nanoparticles for amalgamation of magnetic hyperthermia and chemotherapy: An approach towards enhanced attenuation of tumor. Materials Science & Engineering C.110, 110695.

4. Singh D, Dilnawaz F, Sahoo SK.(2020) Challenges of moving theranostic nanomedicine into the clinic. Nanomedicine (Lond).15(2),111-114.
5. Pradhan J, Mohanty C, Sahoo SK.(2019) Protective efficacy of crocetin and its nanoformulation against cyclosporine A-mediated toxicity in human embryonic kidney cells. Life Sciences. 216, 39 – 48.
6. Chintala R, Dilnawaz F, Panigrahi M, Sahoo SK, Babu PP.(2018) Paclitaxel loaded magnetic nanoparticles induce in vivo tumor growth inhibition in a rat glioblastoma model. IJPCR.10 (7), 176-182.
7. Arya G, Das M, Sahoo SK.(2018) Evaluation of curcumin loaded chitosan/PEG blended PLGA nanoparticles for effective treatment of pancreatic cancer. Biome & Pharmaco.102, 555-566.
8. Dilnawaz F, Acharya S, Sahoo SK.(2018) Recent trends of nanomedicinal approaches in clinics. Int J Pharm. 538, 263-278.
9. Dilnawaz F, Sahoo SK.(2018) Augmented Anticancer Efficacy by si-RNA Complexed Drug-Loaded Mesoporous Silica Nanoparticles in Lung Cancer Therapy. ACS Applied nanomaterials. 1 (2), 730-740.
10. Parhi P, Suklabaidya S, Sahoo SK.(2017) Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo. Sci Rep. 7(1),5806.
11. Mohanty C, Sahoo SK.(2017) Curcumin and its topical formulations for wound healing applications. Drug Discov Today. 22(10),1582-1592.

12. Singh D, Minz AP, Sahoo SK.(2017) Nanomedicine-mediated drug targeting of cancer stem cells. Drug Discov Today. 22(6),952-959.

13. Kundu P, Das M, Tripathy K, Sahoo SK.(2016) Delivery of Dual Drug Loaded Lipid Based Nanoparticles across the Blood-Brain Barrier Impart Enhanced Neuroprotection in a Rotenone Induced Mouse Model of Parkinson’s Disease. ACS Chem Neurosci. 7(12),1658-1670.

14. Acharya S, Sahoo SK.(2016) Exploitation of redox discrepancy in leukemia cells by a reactive oxygen species nanoscavanger for inducing cytotoxicity in imatinib resistant cells. J Colloid Interface Sci. 467,180-191.

15. Vidyasekar P, Shyamsunder P, Sahoo SK, Verma RS.(2015) Scaffold-free and scaffold-assisted 3D culture enhances differentiation of bone marrow stromal cells. In vitro Cell Dev. Biol. 52(2), 204-17.

16. Mohanty C, Kundu P, Sahoo SK.(2015) Brain Targeting of siRNA via Intranasal Pathway. Curr Pharm Des. 21(31),4606-13.

17. Singh A, Jain S, Senapati S, Verma RS, Sahoo SK.(2015) Magnetic Nanoparticles Labeled Mesenchymal Stem Cells: A Pragmatic Solution towards Targeted Cancer Theranostics. Adv Healthc Mater. 4(14),2078-2089.

18. Dilnawaz F, Sahoo SK.(2015) Therapeutic approaches of magnetic nanoparticles for the central nervous system. Drug Discov Today. 20 (10),1256-64.

19. Vandana M, Sahoo SK.(2015) Synergistic activity of combination therapy with PEGylated pemetrexed and gemcitabine for an effective cancer treatment. Eur J Pharm Biopharm. 94,83-93.

20. Parhi P, Sahoo SK.(2015) Trastuzumab guided nanotheranostics: A lipid based multifunctional nanoformulation for targeted drug delivery and imaging in breast cancer therapy. J Colloid Interface Sci. 451,198-211.
21. Das M, Duan W, Sahoo SK.(2015) Multifunctional nanoparticle-EpCAM aptamer bioconjugates: A paradigm for targeted drug delivery and imaging in cancer therapy. Nanomedicine.11(2),379-89.

22. Misra R, Das M, Sahoo BS, Sahoo SK.(2014) Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation. Int J Pharm. 475(1-2),372-384.

23. Singh A, Sahoo SK.(2014) Magnetic nanoparticles: a novel platform for cancer theranostics. Drug Discovery Today.19(4),474-81.

24. Dilnawaz F, Sahoo SK.(2013) Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model. Eur J Pharm Biopharm. 85(3),452- 62.
25. Hermann PC, Trabulo SM, Sainz B Jr, Balic A, Garcia E, Hahn SA, Vandana M, Sahoo SK, Tunici P, Bakker A, Hidalgo M, Heeschen C.(2013) Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. PLoS One.8(6),e66371.
26. Mohanty C, Das M, Sahoo SK.(2012) Emerging role of nanocarriers to increase the solubility and bioavailability of curcumin. Expert Opinion in Drug Delivery. 9(11),1347-64.
27. Mohanty C, Das M, Sahoo SK.(2012) Sustained wound healing activity of curcumin loaded oleic acid based polymeric bandage in a rat model. Mol Pharm. 9(10),2801-11.

28. Vandana M, Sahoo SK.(2012) Reduced Folate Carrier independent internalization of PEGylated Pemetrexed: A potential nanomedicinal approach for breast cancer therapy. Mol Pharm. 9(10),2828-43.
29. Mitra M, Mohanty C, Harilal A, Maheswari UK, Sahoo SK, Krishnakumar S.(2012) A novel in vitro 3D retinoblastoma model for evaluating chemotherapeutic drugs. Molecular Vision.18,1361-1378.
30. Akhtar J, Mallaredy V, Dandapat J, Maiti P, Sahoo SK, Singh S.(2012) PEGylation of an Osteoclast Inhibitory peptide: Suitable candidate for the treatment of Osteoporosis. Int J Pharm. 434(1-2),429-436.
31. Parhi P, Mohanty C, Sahoo SK.(2012) Nanotechnology based combinational drug delivery: An emerging approach for cancer therapy. Drug discovery today. 17, (17-18),1044-1052.
32. Das M, Sahoo SK.(2012) Folate decorated curcumin loaded nanoparticles reverses multidrug resistance and enhances therapeutic potential of nutlin-3a in retinoblastoma. PLoS One. 7(3), e32920.
33. Misra R, Sahoo SK.(2012) Antibacterial activity of doxycycline-loaded nanoparticles. Methods Enzymol. 509,61-85.
34. Dilnawaz F, Singh A, Mewar S, Sharma U, Jagannathan NR, Sahoo SK.(2012) The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model. Biomaterials.33(10),2936-51.
35. Parveen S, Misra R, Sahoo SK.(2012) Nanoparticles: A Boon to Drug Delivery, Therapeutics, Diagnostics and Imaging. Nanomedicine: Nanotechnology, Biology, and Medicine. USA. 8(2),147-66.
36. Singh A, Dilnawaz F, Sahoo SK.(2011) Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy. PLoS One. 6(11), e26803.
37. Parveen S, Sahoo SK.(2011) Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Europian J of Pharmacology. 670(2-3),372-383.
38. Devilakshmi S, Palanivelu S, Krishnakumar S, Sahoo SK, Verma RS.(2011) Monoclonal antibody for specific targeting of Ep-CAM in various carcinomas. Hybridoma. 30(6),511-518.
39. Behera T, Swain P, Sahoo SK, Mohapatra D, Das BK.(2011) Immunostimulatory effect of Curcumin in fish, Labio rohita. Indian J of Natural Products and Resources. 2(2), 184-188.
40. Acharya S, Sahoo SK.(2011) Sustained targeting of BCR-ABL + leukemia cells by synergistic action of dual drug loaded nanoparticles: An implication for leukemia therapy. Biomaterial.32(24),5643- 62.
41. Misra R, Sahoo SK.(2011) Coformulation of doxorubicin and curcumin in poly (D, L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Molecular Pharmaceutics.8(3),852-66.
42. Arya G, Vandana M, Acharaya S, Sahoo SK.(2011) Enhanced Antiproliferative Activity of Herceptin (HER 2) – conjugated Gemcitabine loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomedicine: Nanotechnology, Biology, and Medicine.7(6), 859-870.
43. Behera T, Swain P, Sahoo SK.(2011) Antigen in chitosan coated liposomes enhances immune responses through parenteral immunization. International Immunopharmacology. 11(8),907-14.
44. Mitra M, Dilnawaz F, Misra R, Harilal A, Verma RS, Sahoo SK, Krishnakumar S. (2011) Toxicogenomics of nanoparticulate delivery of etoposide: Potential impact on nanotechnology in retinoblastoma therapy. Cancer Nano. 2(1-6), 21-36.
45. Acharya S, Sahoo SK.(2011) PLGA nanoparticles containing various anticancer agents and tumor delivery by EPR effect. Advanced Drug Delivery Reviews. 63(3), 170-183.
46. Das M, Dilnawaz F, Sahoo SK.(2011) Targeted nutlin-3a loaded nanoparticles inhibiting p53-MDM2 interaction: Novel strategy for breast cancer therapy. Nanomedicine (Lond). (3), 489-507.
47. Mohanty C, Das M, Kanwar JR, Sahoo SK.(2011) Receptor mediated tumor targeting: An emerging approach for cancer therapy. Curr Drug Deliv 8(1),45-58.
48. Parveen S, Sahoo SK.(2010) Evaluation of Cytotoxicity and Mechanism of Apoptosis of Doxorubicin using Folate Decorated Chitosan Nanoparticles for Targeted Delivery to Retinoblastoma. Cancer Nano.(1) 47- 62.
49. Behera AL, Patil SV, Sahoo SK.(2010) Nanosizing of Drugs-APromising Approach for Drug Delivery. A Review International Journal of Pharmacology and Technology. 2(1), 45-56.
50. Vandana M, Sahoo SK.(2010) Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. Biomaterials. 31(35),9340-9356.
51. Misra R, Acharya S, Sahoo SK.(2010) Cancer Nanotechnology: Application of Nanotechnology in cancer therapy, diagnosis and imaging. Drug Discovery Today.15(19-20), 842-850.
52. Mohanty C, Sahoo SK.(2010) The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials. 31(25), 6597- 611.
53. Singh A, Misra R, Mohanty C, Sahoo SK.(2010) Applications of Nanotechnology in Vaccine Delivery. International Journal of Green nanotechnology: Biomedicine. 2(1), B25-B45.

54. Mohanty AK, Dilnawaz F, Mohanty C, Sahoo SK.(2010) Etoposide-loaded biodegradable amphiphilic methoxy (poly ethylene glycol) and poly (epsilon caprolactone) copolymeric micelles as drug delivery vehicle for cancer therapy. Drug Delivery. 17(5), 330-342.
55. Dilnawaz F, Singh A, Mohanty C, Sahoo SK.(2010) Targeted dual drug loaded superparamagnetic iron oxide nanoparticles for cancer therapy. Biomaterials. 31(13), 3694-3706.
56. Mohanty C, Acharya S, Mohanty AK, Dilnawaz F, Sahoo SK.(2010) Curcumin encapsulated MePEG/ PCL block copolymeric micelles: A novel controlled delivery vehicle for cancer therapy. Nanomedicine. 5(3), 433-449.
57. Misra R, Sahoo SK.(2010) Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. European J of Pharmaceutical Sciences. 39(1-3),152-163.
58. Behera T, Nanda PK, Mohanty C, Mohapatra D, Swain P, Das BK, Routray P, Mishra BK, Sahoo SK.(2010) Parenteral immunization of fish, Labeo rohita with Poly D, L-lactide-co-glycolic acid (PLGA) encapsulated antigen microparticles promotes innate and adaptive immune responses. Fish and Shellfish Immunology. 28(2), 320-325.

​Nanotechnology (Cancer drug delivery)

Priya Singh ILS – SRF Research interest – Targeting metabolic reprogramming of breast cancer stem cells by employing phytonanomedicinal approach

Priyanka Mohapatra DST INSPIRE – SRF Research interest – Epigenetic modulation of breast cancer stem cells by phytonanomedicinal approach

Pratikshya Sa CSIR– SRF Research interest – Chemo sensitization of oral squamous cell carcinoma causing smart polymeric nanoparticle

Auromira Khuntia CSIR– JRF Research interest: – Magnetic nanoparticle based cancer immunotherapy

Sneha Dutta UGC-JRF Research interest: – Role of nanomedicine in Chemo immunotherapy

Sonali Sahoo UGC-JRF Research interest: – Role of CAF in tumor microenvironment

Dr. Shasank Sekhar Swain Research Associate Research interest – Structural biology and computer aided drug discovery towards development of potential and less toxic hybrid drug candidates against breast cancer

Rituparna Pal DBT Project JRF

Ankita Mohapatra DBT Project JRF

Somalisa Behera Lab Technician

Sunita Nayak Lab Technician, SEM Facility

Sudhakar Panda DBT Project Assistant

Rojalin Priyadarshini DBT Project Assistant

Nanotechnology (Cancer drug delivery)